- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04254172
A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
October 14, 2021 updated by: Pfizer
A SINGLE-SITE, PROSPECTIVE, NATURAL HISTORY LOW INTERVENTIONAL STUDY TO ESTABLISH NORMATIVE DATA OF REAL-WORLD ACTIVITY MEASURES USING WEARABLE SENSORS IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD)
The purpose of this low interventional study is to collect data on everyday movement in boys with Duchenne muscular dystrophy (DMD) using wearable activity sensors.
The activity sensors could provide useful information beyond what is currently collected by functional (movement, strength) assessments in clinic.
This information can help with the understanding of the impact of DMD, and perhaps with how possible treatments can affect this impact.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 12 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Ambulatory boys with Duchenne muscular dystrophy who receive care at Nationwide Children's Hospital
Description
Inclusion Criteria:
- Diagnosis of Duchenne muscular dystrophy confirmed by medical history and genetic testing
- Body weight between 15 and 50 kg
- Receipt of glucocorticoids for 6 months and a stable daily dose for at least 3 months prior to study entry
- Ability to rise from floor within seven (7) seconds and ability to walk
Exclusion Criteria:
- Current exposure to systemic immunosuppressant agents other than glucocorticoids.
- Prior exposure to any gene therapy agent, including exon-skipping and missense agents.
- Exposure to other investigational drugs within 30 days or 5 half-lives, whichever is longer.
- Any injury which may impact functional testing per investigator's judgement. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date at screening.
- Any planned surgeries which may impact physical activity and performance.
- Presence or history of musculoskeletal or neurological disease in addition to DMD.
- Any known allergies or skin reactions to stainless steel, versaflex, and silicon that may cause possible discomfort by wearable sensors.
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, cancer, autoimmune or allergic disease that may interfere with the study conduct as per investigator's judgment, excluding untreated, asymptomatic, seasonal allergies at time of screening.
- Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are Pfizer employees, including their family members, directly involved in the conduct of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Single cohort
There is no randomization or stratification in this study.
All subjects will complete the same study assessments.
|
Wrist and ankle sensors to be worn continuously for 2-week intervals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change from baseline and variability of activity measures
Time Frame: baseline, 3, 6, 9, and 12 months
|
baseline, 3, 6, 9, and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change from baseline in functional assessment scores obtained in the clinic
Time Frame: baseline, 3, 6, 9, and 12 months
|
baseline, 3, 6, 9, and 12 months
|
Comparison of mean changes from baseline and correlation coefficient between activity monitoring data and functional data obtained in clinic
Time Frame: baseline, 3, 6, 9, and 12 months
|
baseline, 3, 6, 9, and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 19, 2020
Primary Completion (Actual)
August 19, 2020
Study Completion (Actual)
August 19, 2020
Study Registration Dates
First Submitted
January 31, 2020
First Submitted That Met QC Criteria
January 31, 2020
First Posted (Actual)
February 5, 2020
Study Record Updates
Last Update Posted (Actual)
October 15, 2021
Last Update Submitted That Met QC Criteria
October 14, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C3391005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy (DMD)
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
-
Ondokuz Mayıs UniversityCompletedDuchenne Muscular Dystrophy (DMD)Turkey
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Parent Project, ItalyCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
GenethonInstitute of MyologyCompletedDuchenne Muscular Dystrophy (DMD)France
Clinical Trials on Activity Monitor
-
Weill Medical College of Cornell UniversityWeill Cornell Medical College in QatarWithdrawn
-
KU LeuvenUniversitaire Ziekenhuizen KU LeuvenCompletedStroke | Hip Fractures | Abdominal InjuryBelgium
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedPhysical ActivityUnited States
-
Imperial College LondonRecruitingBreast Cancer | Mobility LimitationUnited Kingdom
-
University Hospital, MontpellierRecruitingLow Back Pain, RecurrentFrance
-
Hacettepe UniversityCompleted
-
Christian RiberholtSENS Innovation ApsActive, not recruiting
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)CompletedPhysical ActivityUnited States
-
Boston Children's HospitalCompleted